Listed by the USPTO as MOEHLMAN, ANDREW TERRY
Tech Center 1600 • Art Units: 1628 1655
This examiner grants 67% of resolved cases
MOEHLMAN, ANDREW TERRY works in tech center 1600 and art unit 1628. The profile covers 100 resolved cases and shows an allowance rate of 67.0%. The median time to allowance is 1193 days. Interview lift is 59.7%, associating interviews with a substantial improvement over the overall allowance result.
The principal companies are University of Florida Research Foundation Inc., Genentech Inc., and Nestlé S.A. The principal firms are BAKER BOTTS L.L.P., Berg Hill Greenleaf & Ruscitti LLP, and BIRCH STEWART KOLASCH & BIRCH, LLP. Interview preparation is a material planning consideration, particularly where claim issues can be addressed through focused discussion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18031505 | SELF-ASSEMBLING URICASE FUSION PEPTIDES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18820925 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA | Non-Final OA | Genentech, Inc. |
| 18843065 | USE OF A COMPOSITION FOR MANAGING POSTPRANDIAL GLUCOSE RESPONSE AND ASSOCIATED DISORDERS | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17788239 | BACTERIAL CONSORTIUM COMPRISING AT LEAST ONE BACILLUS AND LACTOBACILLUS STRAIN FOR GLUTEN DEGRADATION | Non-Final OA | Evonik Operations GmbH |
| 18346095 | SURFACE DISPLAYED ENDOGLYCOSIDASES | Non-Final OA | Clara Foods Co. |
| 18262338 | Gut Microbiome as a Predictive Biomarker of Outcomes for Chimeric Antigen Receptor T-Cell Therapy | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17433904 | COMPOSITION CONTAINING PLANT-DERIVED EXTRACT AND/OR PLANT-DERIVED PROCESSED PRODUCT | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18401960 | Method for Secretory Production of Unnatural-Amino-Acid-Containing Protein | Non-Final OA | AJINOMOTO CO., INC. |
| 17277617 | PLANT PROTEIN AND ITS METHOD OF PREPARATION | Non-Final OA | ROQUETTE FRERES |
| 18547679 | Polypeptide Variants | Final Rejection | Novozymes A/S |
| 17801033 | DEVICE FOR EVALUATING STATE OF SAMPLE, SYSTEM CONTAINING SAME, METHOD FOR EVALUATING STATE OF SAMPLE AND LACTATE DEHYDROGENASE USED THEREFOR | Final Rejection | KIKKOMAN CORPORATION |
| 18688617 | METHODS OF PRODUCING HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF | Non-Final OA | Amyris, Inc. |
| 18527564 | AGAR HYDROLYSIS PRODUCT HAVING HYALURONIDASE INHIBITORY ACTIVITY AND USES THEREOF | Non-Final OA | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY |
| 18030883 | TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF | Final Rejection | DSM Austria GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy67.0% of resolved applications examined by Andrew Terry Moehlman were allowed (100 resolved cases), compared with 26.0% across Art Unit 1628 over the last five years.
This examiner's interview lift is +59.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Andrew Terry Moehlman took 1,193 days on average from filing to allowance.
Andrew Terry Moehlman examines applications in Art Unit 1628 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
